US 2008/0075706 A1Published application

Pharmaceutical formulation

AssigneeKAI Pharmaceuticals, Inc.

InventorMike LI

Life of this patent

Estimating the term…

A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.

Dependent claims

A pharmaceutical formulation, comprising:

a protein kinase C modulatory peptide chemically coupled to a transport peptide;
and
a sugar, wherein mannitol and the peptide/transporter conjugate are present in a ratio from about 100:1 to about 1:1.

Dependencies are inferred from the claim text.

A61K 47/26
Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite: carbohydrates, e.g. sugar alcohols,…
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/19
Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles: lyophilised , i.e.…
A61K 38/08
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 5 to 11 amino acids

From the US filing history. Foreign family members aren’t listed.

Loading patent…

A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.

Facts

Application

11/849,929Filed 4 Sep 2007

Priority

30 Sep 2004

Published

27 Mar 2008

Term ends

Not estimatedThe source records don’t support an estimate.

A61K 47/26
Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite: carbohydrates, e.g. sugar alcohols,…
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/19
Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles: lyophilised , i.e.…
A61K 38/08
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 5 to 11 amino acids

Family

Application60/615,486Us provisional application · filed 30 Sep 2004

Application11/240,962Division · filed 30 Sep 2005

Application11/849,929Division · filed 4 Sep 2007

US 2006/0153867 A1Published application

US 2008/0075706 A1This patent

From the US filing history. Foreign family members aren’t listed.